Therapeutic Asset Ratings
427 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Tamsulosin
Prostate Cancer
Turku University Hospital
P4
BB
(64)
CTT-1057
Prostate Cancer
Novartis Pharmaceuticals
P3
BB
(64)
CYPROTERONE
Prostate Cancer
Bayer
P3
BB
(64)
FCH
Prostate Cancer
ITEL Telecomunicazioni Srl
P3
BB
(64)
Histrelin
Prostate Cancer
Mayo Clinic
P3
BB
(64)
Fluciclovine
Prostate Cancer
Blue Earth Diagnostics
P4
B
(63)
PIFLUFOLASTAT
Prostate Cancer
Novartis Pharmaceuticals
P4
B
(63)
Rocuronium
Prostate Cancer
Memorial Sloan Kettering Cancer Center
P4
B
(63)
VIPIVOTIDE TETRAXETAN
Prostate Cancer
Mayo Clinic
P4
B
(63)
TAMOXIFEN
Prostate Cancer
University Health Network, Toronto
P3
B
(63)
Ptvg-Hp
Prostate Cancer
University of Wisconsin, Madison
P2
B
(63)
ROSOPATAMAB
Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited
P2
B
(63)
LIDOCAINE
Prostate Cancer
University of Washington
P4
B
(62)
Cyclophosphamide
Prostate Cancer
Icahn School of Medicine at Mount Sinai
P3
B
(62)
Epirubicin
Prostate Cancer
Icahn School of Medicine at Mount Sinai
P3
B
(62)
Inno-206
Prostate Cancer
University of California, San Francisco
P3
B
(62)
Irinotecan
Prostate Cancer
Fred Hutchinson Cancer Center
P3
B
(62)
Pembrolizumab
Prostate Cancer
Icahn School of Medicine at Mount Sinai
P3
B
(62)
(+)-VINCRISTINE
Prostate Cancer
Fred Hutchinson Cancer Center
P3
B
(62)
Benadryl
Prostate Cancer
Merck Sharp & Dohme LLC
P4
B
(61)
Metformin
Prostate Cancer
University of Arkansas
P4
B
(61)
TESTOSTERONE CIPIONATE
Prostate Cancer
University of Miami
P4
B
(61)
TESTOSTERONE UNDECYLATE
Prostate Cancer
Roswell Park Cancer Institute
P4
B
(61)
Apalutamide
Prostate Cancer
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
P3
B
(61)
Capivasertib
Prostate Cancer
VA Office of Research and Development
P3
B
(61)
Showing 26 to 50 of 427 assets
Previous
Page 2 of 18
Next